[Synergism of PGI2 and molsidomine in arterial occlusive disease].
In order to test the hypothesis, whether molsidomine acts as an in-vivo NO-donor, we examined the synergism of PGI2 and molsidomine in patients with peripheral vascular disease. The effect was quantified by measuring the platelet uptake at atherosclerotic lesion sites, as well as measuring the platelet survival after radiolabelling the autologous platelets with 111Indium-oxine. The combination of both substances achieved a significantly higher (p less than 0.01) benefit in comparison to single administration of either of the components. This synergism was shown via a decrease in thrombogenicity and a prolongation in platelet survival. These data indicate that a potentiating synergism of hemostatic regulation can be achieved via an in-vivo interaction between NO and PGI2.
Sinzinger
H
H
Wilhelm Auerswald-Atheroskleroseforschungsgruppe (ASF) Wien, Osterreich.
D001157:Arterial Occlusive Diseases / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D003328:Coronary Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000008:administration & dosage*; D006801:Humans; D008981:Molsidomine / Q000008:administration & dosage*; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D010974:Platelet Aggregation / Q000187:drug effects* / Q000502:physiology; D015996:Survival Rate
D008981:Molsidomine; D011464:Epoprostenol
Synergismus von PGI2 und Molsidomin bei arterieller Verschlusskrankheit.